Product Overview
[Drug name]
Generic name: Bromocriptine Mesilate Tablets
Trade name: Baimoting
English name: Bromocriptine Mesilate Tablets
Chinese Pinyin: Jiahuangsuan Xiuyinting Pian
[Ingredients]
The active ingredient of this product and its chemical name: Bromocriptine Mesilate.
[Properties]
This product is a white tablet with a notch in the middle of one side and 2.5 engraved on the other side.
[Indications]
It is used for endocrine system diseases, non-prolactin-dependent infertility, hyperprolactinoma, acromegaly, inhibition of physiological lactation, benign breast diseases, nervous system diseases, etc.
[Usage and Dosage] It should be taken orally during meals. 1. Abnormal menstrual cycle and infertility: Take 1/2 tablet (1.25 mg of bromocriptine mesylate) once as needed, 2-3 times a day. If necessary, the dose can be increased to 1 tablet (2.5 mg of bromocriptine mesylate) once, 2-3 times a day. Treatment should be continued until the menstrual cycle returns to normal and/or ovulation resumes. If necessary, treatment can be continued for several cycles to prevent recurrence. 2. Hyperprolactinemia: 1/2 tablet (1.25 mg as bromocriptine mesylate) 2-3 times a day as needed, gradually increasing to 4-8 tablets/day (10-20 mg as bromocriptine mesylate). The specific regimen should be determined based on clinical efficacy and side effects. 3. Acromegaly: The recommended starting dose is 1-1.5 tablets per day (with bromocriptine mesylate
[Adverse Reactions]
1. Many patients may experience nausea, vomiting, headache, dizziness or fatigue in the first few days after taking the drug, but there is no need to stop the drug. Taking certain antiemetics such as chloranil, tamoxifen, metoclopramide, etc. 1 hour before taking bromocriptine mesylate can suppress nausea and dizziness. 2. In very rare cases, postural hypotension occurs after taking this product, so it is recommended that standing blood pressure should be measured for patients who can walk. 3. When treated with high doses, hallucinations, confusion, visual impairment, movement disorders, dry mouth, constipation, Leg cramps, etc. These side effects are approximately dose-dependent, and reducing the dose can control the symptoms. In long-term treatment, especially for those with a history of Raynaud's phenomenon, reversible hypothermia-induced pallor of the fingers and toes may occur occasionally. 4. There have been case reports of patients abroad using dopamine receptor agonists to treat Parkinson's disease who developed pathological gambling, increased libido, and hypersexuality, especially at high doses, which can generally be reversed by reducing the therapeutic dose or stopping the drug.
[Contraindications]
Those who are allergic to any of the ingredients in bromocriptine mesylate tablets are prohibited. In psychiatry, spontaneous and familial tremors, Huntington's chorea, It is contraindicated for patients with severe cardiovascular disease, various types of endogenous mental illness, untreated hypertension, pregnancy toxemia, allergies to other ergot alkaloids, and patients with existing valvular disease.
[Precautions]
1. After treatment with bromocriptine mesylate tablets, fertility may be restored, so women of childbearing age who do not want to get pregnant should be advised to take reliable (non-hormonal) contraceptive measures. Women of childbearing age who want to get pregnant should immediately stop bromocriptine mesylate tablets treatment after pregnancy has been confirmed. The incidence of miscarriage has not increased after discontinuation of the drug, and bromocriptine mesylate tablets have no side effects on early pregnancy (within 8 weeks). Patients with pituitary adenomas should stop taking bromocriptine mesylate tablets. When pregnant after taking bromocriptine tablets, the entire pregnancy should be closely monitored, and regular visual field examinations are necessary. 2. Patients with pituitary adenomas should be re-treated with bromocriptine mesylate tablets when there are signs of tumor enlargement. When treating breast pain and nodular and/or cystic breast disease, the possibility of malignancy should be ruled out first. 3. This product is used to inhibit postpartum lactation, especially in the first week of treatment. It is recommended to check blood pressure at irregular intervals. Once hypertension occurs, accompanied by persistent severe headaches, the medication should be stopped immediately and the patient should be closely observed. 4. For patients with acromegaly with a history of gastrointestinal bleeding, it is best to use alternative treatment options, such as If they must take bromocriptine mesylate tablets, they should also be informed to report any gastrointestinal reactions to medical staff in a timely manner. 5. Patients with a history of mental illness or severe cardiovascular disease need to be cautious when taking large doses of bromocriptine mesylate. 6. When treating female patients not related to hyperprolactinemia, the lowest effective dose should be given to avoid plasma prolactin levels below normal levels, otherwise it may cause luteal dysfunction. Postmenopausal women should be examined every six months. Please read the instructions carefully and use as directed by your doctor.
[Use in special populations]
Children's precautions: There is no safety and safety data for children under 15 years old. Effectiveness research data.
Precautions during pregnancy and lactation: 1. Women who are breastfeeding should not take bromocriptine mesylate tablets. 2. After pregnancy, this product should usually be discontinued after the seventh menstrual period. Pituitary tumors sometimes grow rapidly during pregnancy, which can also occur in women who are able to become pregnant after treatment with bromocriptine mesylate tablets. For the sake of caution, patients should be closely monitored for signs of pituitary enlargement so that bromocriptine mesylate tablets can be used again when necessary. 3. In special circumstances such as after miscarriage, stillbirth, and neonatal death, it is used to suppress postpartum lactation under the guidance of a doctor. It is not recommended as a routine method to suppress physiological lactation. Medication. 4. Postpartum or puerperal women with hypertension, coronary heart disease and/or a history of severe mental illness should not use this product. Postpartum women receiving bromocriptine mesylate tablets should pay attention to monitoring blood pressure, especially in the elderly who are treated. Note: There is no safety and efficacy research data.
[Drug Interactions]
When using this product, please use the following drugs with caution: 1. Erythromycin (the serum concentration of bromocriptine mesylate tablets may increase); 2. Dopamine antagonists such as phenylpromethazine and phenothiazines (may reduce the effect of bromocriptine mesylate tablets). 3. Antipsychotic drugs (hyperprolactinemia antagonists). 4. Smooth muscle spasmolysis 1. Isomethine (increases the toxicity of bromocriptine mesylate tablets). 2. Macrolide antibiotics (may increase the plasma concentration of bromocriptine mesylate tablets, thereby increasing their toxicity). 3. Somatostatin octapeptide (increases the concentration of bromocriptine mesylate tablets). 4. Phenylpropanol (increases the toxicity of bromocriptine mesylate tablets). Avoid simultaneous use with other ergot alkaloid derivatives.
[Pharmacological action] Not yet clear.
[Storage] Shade from light and store in a sealed container.
[Specification] 2.5 mg
[Packing specification] 30 tablets/box.
[Validity period] 36 months
[Approval number] H20160170
